Core Insights - The article highlights the successful participation of Sunflower Group at the 91st National Pharmaceutical Trade Fair and China International Health Nutrition Expo in Nanjing, where it showcased its brand "Wen Dong Fang" and won the "Innovation Pioneer - Industrial Enterprise Award" [3] Group 1: Company Achievements - Sunflower Group's health segment, in collaboration with its liquor division, has gained significant attention for its cross-industry innovation approach, emphasizing "brewing with a pharmaceutical heart" [3] - The "Wen Dong Fang" liquor has been well-received due to its pharmaceutical-grade quality control standards and the integration of traditional techniques with modern technology, leading to high demand and successful sales during the event [5] Group 2: Product Quality and Innovation - The "Wen Dong Fang" team undertook a three-year journey to select high-quality chestnuts from the "Hometown of Chinese Chestnuts" in Qianxi, Hebei, ensuring that each chestnut meets pharmaceutical-grade standards, with iron content in century-old trees being 2.1 times that of younger trees [9] - The production process combines traditional chestnut liquor brewing techniques with modern biological extraction technology, enhancing the absorption of herbal active ingredients while maintaining a low yield of 1 jin of liquor from 12 jin of chestnuts [9] Group 3: Market Positioning and Recognition - "Wen Dong Fang" is recognized as a pioneer in herbal chestnut liquor, catering to diverse consumer needs with products like "Wen Dong Fang No. 6" and "Wen Dong Fang No. 9," designed for casual drinking and gifting [9] - The brand has received authoritative recognition from industry experts and has been featured in a CCTV program, enhancing its credibility and public awareness [9][10]

Group 1 - The fifth meeting of the board of directors of Kew Flower Pharmaceutical Group Co., Ltd. was held on November 18, 2025, via telecommunication voting, with all nine directors participating [2][4]. - The board approved a proposal for product research and development, allocating up to 50 million yuan for projects including traditional Chinese medicine and generic drug development [3][5]. - The decision was made with unanimous support, receiving 9 votes in favor and no opposition or abstentions [4]. Group 2 - The meeting was convened by the chairwoman, Ms. Guan Yuxiu, and the notice and agenda were sent out on November 13, 2025 [2]. - The board's resolutions are valid and do not require submission to the shareholders' meeting for approval [5]. - The company ensures the accuracy and completeness of the information disclosed in the announcement [1].

Core Viewpoint - The company, Kewang Pharmaceutical, has a diverse product portfolio covering various therapeutic areas, including pediatric and adult respiratory medications, indicating a strong presence in the respiratory and general health sectors [1] Product Coverage - The company's products span several treatment areas: children's medications, digestive system, respiratory and cold system, rheumatology, cardiovascular system, gynecology, and general health [1] - In the respiratory and cold treatment area, the company offers a range of pediatric medications, including: - Xiaoer Feire Kechuan Oral Liquid/Granules - Xiaoer Huatan Zhike Granules - Xiaoer Keshuan Ling - Xiaoer Chaigui Antipyretic Granules - Ibuprofen Suspension Drops/Liquid - Roxithromycin Granules - Azithromycin Dry Suspension [1] - For adult respiratory medications, the company provides: - Ganmaoling Capsules/Granules - Compound Acetaminophen and Amantadine Capsules/Granules/Tablets - Ambroxol Hydrochloride Oral Solution - Roxithromycin Dispersible Tablets/Capsules - Pudilan Anti-inflammatory Tablets - Compound Honeysuckle Granules - Azithromycin Capsules/Tablets [1]

Core Points - The company, Kew Flower Pharmaceutical Group Co., Ltd., announced a board resolution on November 18, 2025, to allocate up to 50 million yuan for product research and development, focusing on traditional Chinese medicine, generic drug consistency evaluation projects, and expanding indications for existing products [1][2] - The board meeting was conducted via telecommunication, with all 9 participating directors voting in favor of the proposal, indicating unanimous support for the R&D initiatives [1] - The R&D investment aims to optimize the product structure and enhance the company's core competitiveness, reinforcing its long-term development strategy in the pharmaceutical sector [2] Summary by Categories R&D Investment - The company plans to invest no more than 50 million yuan in R&D, targeting three main areas: traditional Chinese medicine, generic drug consistency evaluation, and expanding indications for existing products [1] - This investment is intended to enrich the product pipeline and strengthen the company's long-term growth potential [1][2] Board Meeting Details - The fifth board's thirteenth meeting was held on November 18, 2025, with all 9 directors participating and voting unanimously in favor of the R&D proposal [1] - The decision falls within the board's authority and does not require shareholder approval, allowing management to control the project’s progress [1] Strategic Focus - Kew Flower Pharmaceutical continues to focus on its core pharmaceutical business, with this R&D funding expected to enhance its position in the innovation of traditional Chinese medicine and the quality improvement of generic drugs [2]

Core Viewpoint - Kew Flower Pharmaceutical announced the convening of its 13th board meeting of the 5th session on November 18, 2025, to discuss product research and development initiatives [1] Company Summary - For the first half of 2025, Kew Flower Pharmaceutical's revenue composition was 99.61% from the pharmaceutical industry and 0.39% from other businesses [1] - As of the report date, Kew Flower Pharmaceutical has a market capitalization of 8.7 billion yuan [1]

Group 1 - The company, Kew Flower Pharmaceutical (002737.SZ), announced a plan to invest up to 50 million yuan for the development of traditional Chinese medicine with the same name and formula, generic drug projects aligned with consistency evaluation, and research to expand indications for existing products [1] - The management has been authorized to oversee the progress and specific matters related to the project development [1] - This initiative aims to enrich the product pipeline and strengthen the company's long-term development momentum [1]

Group 1 - The company, Kew Flower Pharmaceutical (002737.SZ), announced a plan to invest up to 50 million yuan for the development of traditional Chinese medicine with the same name and formula, generic drug projects aligned with consistency evaluation, and research to expand indications for existing products [1] - The management has been authorized to oversee the progress and specific matters related to the project development [1] - This initiative aims to enrich the product pipeline and strengthen the company's long-term development momentum [1]

Core Viewpoint - The company has approved a funding of up to 50 million yuan for various drug development projects, indicating a strategic focus on expanding its product offerings and enhancing its research capabilities [1] Group 1: Product Development Initiatives - The company will initiate research and development for traditional Chinese medicine with the same name and formula [1] - The company plans to develop generic drugs that are equivalent to the consistency evaluation projects [1] - There will be efforts to expand existing products by adding new indications [1] Group 2: Management and Oversight - The management team has been authorized to oversee the progress and specific matters related to the R&D projects [1] - The decision falls within the board's authority and does not require shareholder approval [1]

会议应参加表决董事 9 人，实际参加表决董事 9 人。本次会议召集、召开程 序符合《公司法》及相关法律、法规以及《公司章程》之规定。会议决议合法有 效。 二、董事会会议审议情况 证券代码：002737 证券简称：葵花药业 公告编号：2025-075 葵花药业集团股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事 会第十三次会议于 2025 年 11 月 18 日上午 9 时以通讯表决方式召开。会议由公 司董事长关玉秀女士召集，会议通知及议案于 2025 年 11 月 13 日通过电子邮件 形式发出。 三、备查文件 1、公司第五届董事会第十三次会议决议 特此公告。 1、审议通过《关于产品研发立项的议案》 为丰富产品管线，蓄力长期发展势能，同意公司自筹资金不超过 5,000 万元 立项开展中药同名同方药研发、化药仿制药视同一致性评价项目研发、现有产品 增加适应症研发工作。授权经营管理层对项目研发进度等具体事项进行管控。 表决结果： ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-074 葵花药业集团股份有限公司 | 序 | | | | 金额 | | | 预期年化收 | 资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 签约机构 | 产品名称 | 产品类型 | | 起息日 | 到期日 | | | | 号 | | | | （万元） | | | 益率 | 来源 | | | 招商银行 | 招商银行聚益生金系 | 固定收益类 | | | | | 闲置 | | 1 | 哈尔滨平 | 列公司（35 天）B 款 | 非保本浮动 | 20,000.00 | 2025.11.14 | 2025.12.19 | | 2.1% 自有 | | | 房支行 | 理财计划 | 收益型 | | | | | 资金 | | | | 合计 | | 20,000.00 | | | | | 注：公司与上述签约机构不存在关联关系。 二、投资风险及风险控制措施 1 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性 ...